TMPRSS2 and prostate neoplasm: Assume true fusion occurs in less than 2% of samples, as TMPRSS2-ERG achieves the highest occurrence to date at 0.953% of all TCGA tumor samples [28] (14.657% occurrence rate in prostate tumor samples).